Welcome to Medications.com

Actiq News

Cephalon Pays $425 Million For Off-Label Marketing Dispute - InjuryBoard.com

Allegations of off-label marketing have been suggested in the case of both Fentora and Actiq. Allegedly Fentora and Actiq were marketed as acceptable drugs ...

http://houston.injuryboard.com/de... | Posted: Tue Nov 13 12:19:10 -0500 2007

Barr's 3Q profit falls on charges - CNNMoney.com

The increase in sales is partly attributed to Pliva's product line and a generic version of Actiq launched in 2006. Meanwhile, sales of the company's ...

http://money.cnn.com/news/newsfee... | Posted: Thu Nov 08 08:33:28 -0500 2007

Cephalon Swings to 3Q Loss on Settlement - CNNMoney.com

Sales of the company's pain drug, which includes Actiq, plunged 33 percent to $121.8 million on generic competition. Sales of central nervous system drugs ...

http://money.cnn.com/news/newsfee... | Posted: Thu Nov 08 18:03:15 -0500 2007

Cephalon to settle US, state probes - Philadelphia Inquirer

Sales of the company's pain medications, including Actiq, which is facing generic competition, sank 33 percent. Actiq sales were $56 million, compared with ...

http://www.philly.com/philly/busi... | Posted: Fri Nov 09 03:07:19 -0500 2007

Cephalon Wheels and Deals - Motley Fool

Adjusted net income declined 30% because of increasing competition from Barr Pharmaceuticals (NYSE: BRL) and its generic version of Cephalon's ACTIQ ...

http://www.fool.com/investing/hig... | Posted: Fri Nov 09 16:22:00 -0500 2007

Cephalon to settle US, state probes - Philadelphia Inquirer

Sales of the company's pain medications, including Actiq, which is facing generic competition, sank 33 percent. Actiq sales were $56 million, compared with ...

Posted: Fri Nov 09 03:07:19 -0500 2007

TO THE POINT - Investor's Business Daily (subscription)

The company's generic product sales doubled to $434 mil on its Pliva product, a knockoff of Actiq. It sees Q4 EPS of 73-83 cents vs. views of 83 cents. ...

Posted: Thu Nov 08 20:19:59 -0500 2007

Cephalon Swings to 3Q Loss on Settlement - CNNMoney.com

Sales of the company's pain drug, which includes Actiq, plunged 33 percent to $121.8 million on generic competition. Sales of central nervous system drugs ...

Posted: Thu Nov 08 18:03:15 -0500 2007

Cephalon Wheels and Deals - Motley Fool

Adjusted net income declined 30% because of increasing competition from Barr Pharmaceuticals (NYSE: BRL) and its generic version of Cephalon's ACTIQ ...

Posted: Fri Nov 09 16:22:00 -0500 2007

Barr Reports Third Quarter 2007 GAAP Earnings of $0.36 Per Share ... - PR Newswire (press release)

The increase also reflects strong sales of Fentanyl Citrate, a generic version of ACTIQ(R) that we launched in late September 2006. ...

http://www.prnewswire.com/cgi-bin... | Posted: Thu Nov 08 07:45:15 -0500 2007




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea